Pfizer (PFE) stock in red as the company reports a patient death in a clinical trial for its hemophilia therapy Hympavzi.

Given the size of the stroke depicted in Figure 1 (greater than one third of the hemisphere), thrombolytic therapy would be contraindicated for this patient. Indications of a hemorrhagic stroke ...

In a letter to the hemophilia community, Pfizer Inc. reported a death due to cerebellar infarction and subsequent cerebral hemorrhage in a long-term extension trial participant taking the New ...

Investing.com -- A patient died after receiving Pfizer Inc.’s (NYSE:PFE) hemophilia drug Hympavzi, adding to challenges for ...